Anthem Biosciences, a leading contract research, development and manufacturing organisation (CRDMO), is set to scale up its infrastructure to meet the surging global demand for fermentation-based APIs and complex custom synthesis projects.

The company recently operationalised its third manufacturing unit in Karnataka, dedicated to peptides and fermentation, which involved an investment of Rs 600 crore. A fourth large-scale facility, spanning 30 acres—larger than Units 1, 2, and 3 combined is underway, and expected to be functional within two years. Anthem’s gross block exceeds Rs 1,300 crore, with Rs 300 crore in ongoing capital work-in-progress.

With over 80 percent of revenue from exports to the US, Europe, and China, Anthem focuses on high-margin products like probiotics, enzymes, peptides, and vitamins. It partners directly with global innovators, supporting New Drug Applications (NDAs) through advanced intermediates and APIs. 

This strategic growth comes as the company prepares for a Rs 3,395-crore initial public offering (IPO), scheduled to open from July 14 to 16.